Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
about
Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cellsImmunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesHerpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantationComplementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation eventA phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.Secondary cancers following allogeneic haematopoietic cell transplantation in adults.Graft-vs-host disease following allogeneic hematopoietic cell transplantation.A 47-year-old stem cell transplant recipient with fever, cough and chest pain.Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation.ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder.Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
P2860
Q28484266-4C11B562-0C20-45DA-9AAF-C0469E130985Q33795160-FACFD007-CC3B-45E1-95DA-AD159C316D50Q35017153-27D17610-6B32-42CD-A650-A643F0F408E4Q35142912-2C5B3B79-86E7-4FB7-B324-6D838371CEBAQ35166811-2C43CC91-5961-4CE5-A69B-ACB85C8840DFQ36173285-734E82CD-11E0-4B66-AECE-6C20271CC75BQ36519976-06F7BA2D-869D-4D79-B3EE-B9F3202FE967Q36592428-81FD1D1A-1C32-424D-933D-3EA8E2D14013Q37880254-6E9BD83B-0E99-4155-BE9C-5EBB77F03A87Q37942818-094F74E4-CA59-45C8-896A-19F9DC3AE739Q40152435-E1E64EC3-627D-447B-8B66-AF1D85559859Q41549338-A6B26854-4793-4E8E-A826-33F398DDEE44Q41623045-ECA01C0F-44AC-4B0D-A2E5-23E7A68873EDQ41688144-9C14238D-1847-41F3-A33B-C28A7B86D49FQ44150295-9FF686B8-87B3-4BFB-8642-0347F2411D39Q45351139-3364EAB1-D108-4DFC-9B7C-B7E47B472244Q45351795-9C5EBE9B-083B-4D21-9C6F-B6D972F7425FQ45352633-9EAC0DC6-7A5D-4F97-8753-B27BEE481086Q45764128-CE6D5D17-74C0-4E65-A881-4A268D56E4E5Q47114028-FC663E67-693D-476B-AC26-EA4656B35D97Q48806049-1674C3B6-1AA9-4D97-A316-9D5430356D9AQ50935631-9EDCF0EF-2130-4931-89AA-7A26CB8E0462Q54216562-B5911CF6-F3E9-45C9-8B97-4D9F91DB24B6Q54379261-80FE64E4-A309-449D-807E-648268135851
P2860
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@ast
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@en
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders
@nl
type
label
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@ast
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@en
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders
@nl
prefLabel
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@ast
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@en
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders
@nl
P2093
P2860
P1476
Strategies to prevent EBV reac ...... ntation in high-risk patients.
@en
P2093
A John Barrett
Bipin N Savani
Katayoun Rezvani
Nishitha Reddy
P2860
P304
P356
10.1016/J.BBMT.2010.08.007
P577
2010-08-21T00:00:00Z